drugset
drugset / Trial / NCT07217119

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

NCT07217119 ↗

Phase 1/2 Active not recruiting 25 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with feladilimab (GSK3359609), and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).

Timeline

Start
2019-11-26
Primary completion
2025-04-17
Completion
2027-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Belantamab mafodotin Monoclonal antibody — —
Subject Feladilimab Monoclonal antibody — —

Indications

plasma cell myeloma